bluuebunny/crossref_metadata_2025_split huggingface dataset:
Discriminating carbon dioxide sources during volcanic unrest: The case of Campi Flegrei caldera (Italy)
Authors: Buono Gianmarco , Caliro Stefano , Paonita Antonio , Pappalardo Lucia , Chiodini Giovanni 
Published: March 2023

AbstractLarge calderas are among the main emitters of volcanic CO2, which is mainly supplied by the deep degassing of magmatic fluids. However, other sources of non-magmatic CO2 can also occur due to the intense interaction among magmatic fluids, wide hydrothermal systems, and their host rocks. In particular, massive amounts of CO2 are released by calderas during unrest phases and have been often detected before eruptions. An accurate assessment of CO2 sources is thus fundamental to properly understand gas monitoring signals during volcanic crises. We focused on the restless Campi Flegrei caldera, in southern Italy, where CO2 fluxes at the Solfatara-Pisciarelli hydrothermal site have been progressively increasing up to 4000–5000 t/d during the ongoing unrest that started in 2005. Theoretical models of magma degassing have been able to reproduce the CO2-N2-He variations at the Solfatara fumaroles. However, a time-dependent deviation between measured and modeled N2/CO2 and He/CO2, well correlated with the temporal evolution of ground uplift and temperature of the hydrothermal system, has been observed since 2005. We show that these variations are controlled by intense physical-chemical perturbation of the hydrothermal system, which is driving the decarbonation of hydrothermal calcite stored in reservoir rocks. This process is providing large volumes of non-magmatic CO2 during the current unrest, contributing up to 20%–40% of the total fumarolic CO2.
Syntectonic sediment loading and fold-thrust belt structural architecture: An example from the central Appalachians (USA)
Authors: Evans Mark A. 
Published: March 2023

AbstractFluid inclusion microthermometry of synkinematic veins is used to estimate the maximum syntectonic load that was deposited on the wedge top in the central Appalachians (northeastern United States) during the Alleghanian orogeny. The restored loads indicate two major depocenters during the Alleghanian orogeny: one above Broadtop synclinorium, with as much as 7 km of Pennsylvanian–Permian load probably sourced by the erosion of rocks uplifted by the growing Blue Ridge massif and emplacement of the North Mountain thrust sheet; the other above the Anthracite belt, with as much as 16 km of syntectonic load likely sourced by the erosion of rocks uplifted by the growing Reading Prong massif. The loads were generally &lt;3 km in the intervening Juniata culmination. In areas of high load, the structural architecture of the basin is that of widely spaced thrusts (~17–22 km) with large leadingedge anticlines in the Cambrian–Ordovician lithotectonic unit, while in areas of low load, thrusts are more closely spaced (~15 km) and deformed into an imbricate stack. The relationship between observed syntectonic loads, thrust spacing, and structural style reflect modeled relationships.
On different modes of a filamentary atmospheric pressure plasma jet: modeling, laser schlieren deflectometric and high-speed camera investigations
Authors: Wolff Thorben , Foest Rüdiger , Kersten Holger 
Published: March 2023

AbstractWe investigated a filamentary non-thermal atmospheric pressure plasma jet used for coating applications. The plasma jet exhibits two different modes, the stationary mode and the locked mode, in which the filaments rotate around the plasma jet axis. We present a model for the modes and verify it by measurements with high-speed camera and laser schlieren deflectometry. Laser schlieren deflectometry investigations reveal a drift of the rotation frequency over time towards lower values. Additionally, relations between the filament rotation frequency and gas flow as well as input power, respectively, are investigated by the laser schlieren deflectometry. Correlation between rotation frequency and gas flow show a linear dependence and with increasing power the rotation frequency increases as well. All the results are in agreement with the proposed model.
Graphical abstract
SLITS: Sparsity-Lightened Intelligent Thread Scheduling
Authors: Jin Wangkai , Peng Xiangjun 
Published: March 2023

A diverse set of scheduling objectives (e.g., resource contention, fairness, priority, etc.) breed a series of objective-specific schedulers for multi-core architectures. Existing designs incorporate thread-to-thread statistics at runtime, and schedule threads based on such an abstraction (we formalize thread-to-thread interaction as the Thread-Interaction Matrix). However, such an abstraction also reveals a consistently-overlooked issue: the Thread-Interaction Matrix (TIM) is highly sparse. Therefore, existing designs can only deliver sub-optimal decisions, since the sparsity issue limits the amount of thread permutations (and its statistics) to be exploited when performing scheduling decisions.
We introduce Sparsity-Lightened Intelligent Thread Scheduling (SLITS), a general scheduler design for mitigating the sparsity issue of TIM, with the customizability for different scheduling objectives. SLITS is designed upon the key insight that: the sparsity issue of the TIM can be effectively mitigated via advanced Machine Learning (ML) techniques. SLITS has three components. First, SLITS profiles Thread Interactions for only a small number of thread permutations, and form the TIM using the run-time statistics. Second, SLITS estimates the missing values in the TIM using Factorization Machine (FM), a novel ML technique that can fill in the missing values within a large-scale sparse matrix based on the limited information. Third, SLITS leverages Lazy Reschedule, a general mechanism as the building block for customizing different scheduling policies for different scheduling objectives. We show how SLITS can be (1) customized for different scheduling objectives, including resource contention and fairness; and (2) implemented with only negligible hardware costs. We also discuss how SLITS can be potentially applied to other contexts of thread scheduling.
We evaluate two SLITS variants against four state-of-the-art scheduler designs. We highlight that, averaged across 11 benchmarks, SLITS achieves an average speedup of 1.08X over the de facto standard for thread scheduler - the Completely Fair Scheduler, under the 16-core setting for a variety of number of threads (i.e., 32, 64 and 128). Our analysis reveals that the benefits of SLITS are credited to significant improvements of cache utilization. In addition, our experimental results confirm that SLITS is scalable and the benefits are robust when of the number of threads increases. We also perform extensive studies to (1) break down SLITS components to justify the synergy of our design choices, (2) examine the impacts of varying the estimation coverage of FM, (3) justify the necessity of Lazy Reschedule rather than periodic rescheduling, and (4) demonstrate the hardware overheads for SLITS implementations can be marginal (<1% chip area and power).
Abstract ED12-3: ATR inhibitors and PARP1 selective PARP inhibitors
Authors: Tutt Andrew 
Published: March 2023

Abstract
The targeting of Homologous Recombination deficient (HRD) malignancy using a synthetic lethal strategy based on the inhibition and trapping of PARP1 on DNA in manner that leads to tumour selective effects via dependency on the function of HR gene products such as BRCA1, BRCA2 and PALB2 for DNA replication fitness is now well established. However, there is a need to improve both the frequency and duration of response in the licensed indications and to explore combination PARP inhibitor (PARPi) strategies that may be effective a broader range of breast cancers with functional deficiencies in HR and the wider DNA damage response. ATR inhibitors exacerbate replication stress that is toxic to HR deficient cells. Combinations of an ATR inhibition (ATRi) and PARPi have been shown to be synergistic and to be active in PARPi resistant pre-clinical model contexts. The development of combination strategies of these agents and of platinums and ATRi have been limited by combinatorial toxicity but have recently reported results in breast cancer. PARP1 is part of a family of PARP enzymes and currently licensed PARPi inhibit several family members that underpin some of their toxicity. New PARP1 selective agents have recently reported results in early phase trials. I will review some of the mechanistic rationale, preclinical data and relevant clinical trial data in my lecture.
Citation Format: Andrew Tutt. ATR inhibitors and PARP1 selective PARP inhibitors [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr ED12-3.
Abstract ED2-3: Hormonal exposure and risk in BRCA1/2 carriers
Authors: Kotsopoulos Joanne 
Published: March 2023

Abstract
Women who inherit a pathogenic variant (mutation hereafter) in the BRCA1 or BRCA2 geneface extremely high lifetime risks of developing breast and ovarian (or fallopian tube) cancer. More than two decades since the discovery of these genes, and primary prevention with bilateral mastectomy and salpingo-oophorectomy remain the most effective options to manage cancer risk in this population. Understanding the impact of exogenous hormone use is important for both the clinical management of high-risk women and for furthering our knowledge of the pathogenesis of BRCA-associated disease. In this session, I will review the current epidemiologic data surrounding the role of exogenous (anti)hormone use on BRCA-cancer risk. Specifically, I will discuss the role of tamoxifen in preventing BRCA-associated breast cancer and I will describe whether use of oral contraceptives or hormone replacement therapy (HRT) increase the risk of breast cancer. Where possible, I will present data by gene mutation. Potential associations with the risk of ovarian cancer will also be referred to, given that managing BRCA-cancer risks is a balancing act. Finally, I will review how the epidemiologic information has contributed to the discovery of novel targets for the non-surgical prevention of BRCA1-associated breast cancer and gaps in the literature to be addressed in future research.
Citation Format: Joanne Kotsopoulos. Hormonal exposure and risk in BRCA1/2 carriers [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr ED2-3.
Abstract ED5-3: Financial toxicity
Authors: Chino Fumiko 
Published: March 2023

Abstract
People with cancer spend more out of pocket for medical care than others with chronic diseases, a pattern that persists years after initial cancer diagnosis and treatment. Patients and their families are at risk for financial toxicity including problems paying medical bills, increased stress and/or symptom burden, and delaying or forgoing care due to costs. In this talk, Dr. Fumiko Chino provides an overview of financial toxicity in cancer care and its real-life impact on people with cancer. Factors contributing to financial toxicity are addressed as well potential solutions.
1. Define financial toxicity as a negative consequence of cancer diagnosis/treatment
2. Describe effects of financial toxicity on quality of life, adherence, and outcomes
3. Name potential solutions to financial toxicity on a health system, provider, and patient level
Citation Format: Fumiko Chino. Financial toxicity [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr ED5-3.
Abstract ED9-2: The contribution of the tumor microenvironment to cancer dormancy
Authors: Bravo-Cordero Jose Javier 
Published: March 2023

Abstract
In this seminar I will discuss how breast cancer DTCs modify the metastatic microenvironment to favor seeding and dormancy. In order to extravasate efficiently and form metastasis, cancer cells have to become migratory and coordinate both invasive and proliferative programs at distant organs. High-resolution lattice light-sheet with adaptive optics imaging in living cells revealed that DTCs extravasate from the blood vessels by forming actin-rich invadopodium protrusions. We have identified a population of breast cancer DTCs with pro-invasive and pro-dormancy capacities. These cells downregulate srGAP1, a GTPase regulator, favoring dissemination and dormancy at metastatic organs. Our findings describe a novel mechanism mediating the shift from a proliferative to an invasive/dormant phenotype in breast cancer cells in vivo. srGAP1 is a new regulator of dormancy that regulates the formation of dormancy-permissive microenvironments through increased secretion of TGFb2 and SMAD2 activation.
Citation Format: Jose Javier Bravo-Cordero. The contribution of the tumor microenvironment to cancer dormancy [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr ED9-2.
Abstract OT3-33-01: Prospective, Multi-Center, Artificial Intelligence Study for Early Prediction of Serious Events under Treatment Is Now Open for Recruitment in Breast Cancer - OMCAT Trial in Progress
Authors: Schinköthe Timo , Tonk Christian Horst , Kates Ronald , Küemmel Sherko , Cardoso Fatima , Harbeck Nadia , Staib Peter , Schmidt Annette 
Published: March 2023

Abstract
Background: Aim of the OMCAT trial (‘One Million CAncer Treatment months’, NCT04531995) is improvement of cancer patient care and safety by developing artificial intelligence (AI)-based, incident prediction algorithms. Incident detection allows early notification of treatment teams, enabling timely management changes or interventions. Ultimately the algorithms can also support improved health resource allocation. This trial in progress aims to provide learning databases in breast cancer comprising both electronic patient reported outcome (ePRO) data using the mobile medical device ‘CANKADO PRO-React’ and ground truth outcome data, which provide disease-specific events of interest (“incidents”) verified by the physician (e.g., during patient examinations). Methods: Incident prediction is posed as an application of stochastic time series analysis using AI and knowledge engineering technology. The learning process begins by fitting individualized and disease-specific stochastic process models to “incident-free” intervals extracted from the ePRO data series. Incidents produce detectable deviations from “ordinary” ePRO fluctuations. The algorithms are trained on CANKADO PRO-React data to produce real-time risk functions for predicting incidents on a clinically specified time horizon. Results: Considering the heterogeneity and combinatorics of diseases, stages, therapies, and types of events considered in this study, ultimately the AI algorithms aim to discover about 360 distinct predictive relationships. The estimate of one million treatment months is derived from statistical power analysis of this target, considering estimated median documentation time of six months per patient and estimated 400-500 patients per predictive relationship. To date, 45 centers in Germany have expressed interest in participating. This participation level will enable proof of principle. Ethics votes are already available in most regions. Other centers are invited to participate in this trial. Conclusions: OMCAT opens a whole new path towards evidence-trained AI and a novel combination of patient observation and predictive care. The goals of OMCAT are ambitious and will therefore require many more supporters.
Citation Format: Timo Schinköthe, Christian Horst Tonk, Ronald Kates, Sherko Küemmel, Fatima Cardoso, Nadia Harbeck, Peter Staib, Annette Schmidt. Prospective, Multi-Center, Artificial Intelligence Study for Early Prediction of Serious Events under Treatment Is Now Open for Recruitment in Breast Cancer - OMCAT Trial in Progress [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT3-33-01.
Abstract P1-05-24: DELAYS in DIAGNOSIS of Adolescent and Young Adult BREAST CANCER and LACK OF BREAST HEALTH EDUCATION, Community Based Research
Authors: Peters Missy , Tubman Steph 
Published: March 2023

Abstract
INTRO) The average AYA breast cancer patient is diagnosed at a higher stage and has a higher mortality rate compared to their 40+ counterparts [1,2,3]. Ruddy et al. (2014) establish a higher prevalence of delayed diagnosis in AYA patients [4]. Delays in treatment of just 6 weeks have been linked to poorer 5-year survival rates [5]. In this study, we attempt to confirm the findings of Ruddy et al. and further define factors affecting delays in diagnosis. METHODS) We distributed an online survey via social media outlets to women diagnosed &lt; 40 years old in the USA. We interpreted 455 responses. RESULTS) Our findings determined that 70% of respondents (n=320) made extra efforts after detecting an abnormality and taking steps to obtain a diagnosis. This includes those with prompt and delayed diagnosis. 36% of survivors faced delays in diagnosis (defined by 8+ weeks duration from detection to diagnosis). 62% of survivors say that a physician never educated them on breast health prior to diagnosis. 54% have not heard of breast self-awareness (BSA) and 54% incorrectly defined breast self-exams (BSE), suggesting confusion in this distinction. DISCUSSION) These data confirm earlier findings that 1) women under 40 face a significant rate of delayed diagnosis; and 2) patient perceptions and medical provider perceptions contribute to these delays. We propose that earlier diagnosis of breast cancer in young women will initiate quicker treatment interventions which have been shown to increase 5-year survival rates and lower long-term mortality rates in the AYA breast cancer population [5,6]. CONCLUSION) Greater efforts should be made to educate young women on breast health, and the medical community should be made aware of these challenges so they can properly evaluate and assist young women to receive a prompt diagnosis.
Young Breast Cancer Project
Summary of poster presented at AACR summarizing our community based research and advocacy efforts for AYA breast cancer in the US.
Citation Format: Missy Peters, Steph Tubman. DELAYS in DIAGNOSIS of Adolescent and Young Adult BREAST CANCER and LACK OF BREAST HEALTH EDUCATION, Community Based Research [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P1-05-24.
Abstract P1-05-34: MicroRNAs as Prognostic Markers in Breast Cancer
Authors: Nguyen Anh Q. , Cunningham Colin , Okpechi Samuel , Yousefi Hassan , McKinney Shawn , Boulmay Brian , Garcia Agustin , Alahari Suresh 
Published: March 2023

Abstract
Background: Breast cancer (BC) is the most common cancer and the second leading cause of cancer death in American women. BC disproportionally affects women of ethnic minorities, especially Black and Hispanic. While this disparity has been acknowledged and social determinations of health remains an important contributor, BC pathophysiology is yet to be elucidated in minorities. MicroRNAs (miRNA), including but not limited to let-7, 125-3p, 192-5p, 451a, play regulatory roles in cancer pathobiology and progression in many cancer types, including but not limited to BC. In our lab, in vitro and in vivo studies on mouse models demonstrated that miR-23b and miR-27b had crucial roles in cancer progression in BC via mechanisms that involves nischarin, an integrin-binding protein, and were associated with worse outcome. Moreover, miRNAs can be detected and are stable in blood samples, and thus the detection has a profound clinical impact on diagnosis. Study Design: Between April 2021 and May 2022, 30 newly diagnosed patients with BC and 30 patients without any cancer diagnosis at University Medical Center- New Orleans were enrolled on the study (IRB# 936). 86% of patients are African American or Hispanics. Plasma samples were collected before any medical intervention for BC. Plasma miRNAs were isolated and miRNA expression were performed utilizing RT-PCR. Results: Expressions of let-7 and 125a miRNAs are two times higher in plasma of patients with BC compared to patients without a diagnosis of cancer. There was no difference in miRNA expression in circulatory 23b, 27b, 192-5p, and 451a. Among breast cancer types, there are two-fold decreased expression of 192-5p and 451a in triple negative compared to hormone positive BC. Conclusion: This project will add to the body of knowledge on roles of miRNAs as prognostic markers in patients with BC, more importantly, triple negative BC, and elucidate pathophysiologic mechanism contributing to racial disparity in breast cancer treatment and recurrence. In the near future, we aim to examine effects of chemotherapy and surgery on the expression of circulatory microRNAs.
Citation Format: Anh Q. Nguyen, Colin Cunningham, Samuel Okpechi, Hassan Yousefi, Shawn McKinney, Brian Boulmay, Agustin Garcia, Suresh Alahari. MicroRNAs as Prognostic Markers in Breast Cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P1-05-34.